Halcon Resources Corp (NYSE:HK) last released its earnings data on Wednesday, July 30th. The company reported $0.07 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.04 by $0.03. The company had revenue of $327.10 million for the quarter, compared to the consensus estimate of $303.63 million. During the same quarter last year, the company posted $0.04 earnings per share. Halcon Resources Corp’s revenue was up 52.6% compared to the same quarter last year. On average, analysts predict that Halcon Resources Corp will post $0.21 earnings per share for the current fiscal year. Halcon Resources Corp. (NYSE:HK) belongs to Basic Materials sector. Its weekly performance is -1.08%. On last trading day company shares ended up $5.50. Halcon Resources Corp. (NYSE:HK) distance from 50-day simple moving average (SMA50) is -12.12%.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has received a $2m milestone as part of a development and license agreement with Avanir Pharmaceuticals for the clinical progression of AVP-786 in patients with major depressive disorder (MDD). The new drug product, AVP-786, is a combination of deuterium modified dextromethorphan and ultra-low dose quinidine. The payment is result of the initiation of dosing by Avanir in a Phase II clinical trial with AVP-786 for the adjunctive treatment in MDD patients. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) shares moved down -1.54% in last trading session and ended the day at $8.96. CNCE return on assets is -28.10%. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) quarterly performance is -2.61%.

Shares of Eastman Chemical Company (NYSE:EMN) have been given an average rating of “Buy” by the thirteen analysts that are currently covering the stock. Six investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $91.36. On 29 August, Eastman Chemical Co. (NYSE:EMN) shares moved up 0.02% and was closed at $82.47. EMN EPS growth in last 5 year was 26.80%. Eastman Chemical Co. (NYSE:EMN) year to date (YTD) performance is 3.01%.

Drug developer Allakos Inc. has raised $24.5 million toward an upsized goal of a $42 million Series A round. The San Mateo company, founded by veterans of KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO), is developing antibody-based drugs against inflammatory diseases, such as asthma, food allergies and gastrointestinal conditions. It is zeroing in on so-called T-helper cells, a type of white blood cell that is dysregulated in allergic diseases and inflammation. KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) ended the last trading day at $1.53. Company weekly volatility is calculated as 4.80%and price to cash ratio as 0.87. KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) showed a weekly performance of 2.68%.

Tech Data Corp (NASDAQ:TECD) last announced its earnings results on Tuesday, August 26th. The company reported $1.12 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.77 by $0.35. The company had revenue of $6.84 billion for the quarter. During the same quarter last year, the company posted $0.73 earnings per share. Tech Data Corp’s revenue was up 8.1% compared to the same quarter last year. Analysts expect that Tech Data Corp will post $5.06 EPS for the current fiscal year. Tech Data Corp. (NASDAQ:TECD) shares moved up 1.05% in last trading session and ended the day on $67.50. TECD Gross Margin is 5.10% and its return on assets is 2.60%. Tech Data Corp. (NASDAQ:TECD) quarterly performance is 12.63%.